immunotherapy
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
FDA accepts biologics license application for MSD’s allergy immunotherapy drug
April 13, 2016Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …
GSK and Adaptimmune expand R&D collaboration
February 3, 2016Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
More breakthroughs in cancer pose the question: Who pays for them?
December 16, 2015Research and Development Cancer, drug access, immunotherapy, oncology
The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …
GSK and Merck to study immunotherapy combo in solid tumours
November 3, 2015Research and Development GSK, Merck, immunooncology, immunotherapy, keytruda, phase I
GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the …
Sanofi and BioNTech in cancer immunotherapy partnership
November 3, 2015Manufacturing and Production, Research and Development BioNTech, Cancer, Sanofi, immunotherapy
Sanofi and BioNTech have agreed a new multi-year exclusive collaboration and license agreement, to discover and develop up to five …
Novartis acquires Admune Therapeutics
October 21, 2015Research and Development Admune Therapeutics, Cancer, Novartis, Palobiofarma, immunotherapy
Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …
FDA grants Opdivo breakthrough status for kidney cancer
September 18, 2015Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma
The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
Bristol-Myers Squibb launches Opdivo in the UK for lung cancer
August 12, 2015Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo
The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …
Sanofi, Evotec and Apeiron partner on immuno-oncology
August 10, 2015Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours
Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
Amgen bets on immunotherapy future
June 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, immunotherapy, oncology, oncolytic, tom lillie
When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
